We could not test whether similar publication bias exists for trials supporting unsuccessful new drug applications because adequate information about these applications was unavailable from the FDA or other government or commercial sources.We also found the reporting of clinical trials in the FDA review documents and drug labels to be variable in detail and content, and not an adequate substitute